Depomed, Inc. (NASDAQ:DEPO) announced today that its president and chief
executive officer, Carl A. Pelzel will be presenting at Canaccord Adams’
29th Annual Global Growth Conference in Boston, Massachusetts
on Thursday August 13th at 10:00 a.m. EDT.
The company will be webcasting its presentation and interested parties
can access the live or archived presentation for up to 90 days on the
company’s website at www.depomed.com.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two product
candidates in Phase 3 clinical development, two approved products on the
market and other product candidates in its early stage pipeline. Product
candidate DM-1796 is in Phase 3 clinical development for the treatment
of neuropathic pain and has been licensed to Solvay Pharmaceuticals.
Product candidate SeradaTM is in Phase 3 clinical development
for menopausal hot flashes. GLUMETZA® (metformin
hydrochloride extended release tablets) is approved for use in adults
with type 2 diabetes and promoted by Santarus, Inc. in the United
States. Proquin® XR (ciprofloxacin hydrochloride) is approved
in the United States for the once-daily treatment of uncomplicated
urinary tract infections. Depomed formulates its products and product
candidates with its proven, proprietary Acuform® drug
delivery technology, which is designed to improve existing oral
medications, allowing for extended, controlled release of medications to
the upper gastrointestinal tract. Benefits of Acuform-enhanced
pharmaceuticals include the convenience of once-daily administration,
improved treatment tolerability and enhanced compliance and efficacy.
Additional information about Depomed may be found on its website, www.depomed.com.
Depomed, Inc.
Sheilah Serradell, 650-462-5900
sserradell@depomed.com
